BioAegis Therapeutics, Inc.

BioAegis Therapeutics, Inc. is a biotechnology company that aims to commercialize groundbreaking discoveries in inflammation and infection. The company's focus lies in restoring plasma gelsolin, a human protein with a crucial clinical role in addressing infectious, inflammatory, and degenerative diseases. Founded in 2011, BioAegis Therapeutics is dedicated to developing high-value, biomarker-directed treatments across a range of indications, aiming to provide solutions for rare orphan indications and major acute and chronic diseases such as trauma, burns, renal disease, and sepsis. The company recently secured a substantial $22.00M in a Venture Round investment on 22 March 2022, signaling investor confidence in the potential impact of its research and products. BioAegis Therapeutics' innovative approach and focus on addressing unmet medical needs position it as a noteworthy player in the fields of biotechnology and health and wellness.